Aimmune Therapeutics

OverviewSuggest Edit

We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization ImmunoTherapy, or CODITTM, is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure, or reduce symptom severity should an allergic reaction occur. CODIT is intended to reduce meaningfully the burden and anxiety experienced by food-allergic patients and their families.

TypePublic
Founded2011
HQBrisbane, CA, US
Websiteaimmune.com
Employee Ratings4.3
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2019)275(+6%)
Share Price (Oct 2020)$34.5
Cybersecurity ratingCMore

Key People/Management at Aimmune Therapeutics

Andrew Oxtoby

Andrew Oxtoby

President & Chief Executive Officer
Eric Bjerkholt

Eric Bjerkholt

Chief Financial Officer
Samina Bari

Samina Bari

Senior Vice President, Corporate Affairs
Fabiana Lacerca-Allen

Fabiana Lacerca-Allen

Senior Vice President, Compliance
Cathy Nolan

Cathy Nolan

Senior Vice President, Strategy, Marketing & Innovation
Douglas Sheehy

Douglas Sheehy

General Counsel and Secretary
Show more

Aimmune Therapeutics Office Locations

Aimmune Therapeutics has offices in Brisbane, Durham, München, Dublin and in 1 other location
Brisbane, CA, US (HQ)
8000 Marina Blvd #200
Durham, NC, US
1005 Slater Rd #300
München, DE
Mies-van-der-Rohe-Straße 6
Dublin, IE
Block B, The Crescent Building
London, GB
10 Eastbourne Terrace, Paddington
Show all (5)

Aimmune Therapeutics Financials and Metrics

Aimmune Therapeutics Revenue

USD

Net income (Q2, 2020)

(69.2m)

EBIT (Q2, 2020)

(66.0m)

Market capitalization (16-Oct-2020)

2.3b

Closing stock price (16-Oct-2020)

34.5

Cash (30-Jun-2020)

266.6m

EV

2.1b
Aimmune Therapeutics's current market capitalization is $2.3 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

16.2m26.9m43.9m81.9m125.8m

R&D expense

19.8m54.6m89.3m133.4m124.0m

Operating expense total

36.0m81.5m133.3m215.3m249.8m

EBIT

(36.0m)(81.5m)(133.3m)(215.3m)(249.8m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

575.0k

Cost of goods sold

257.0k4.9m

Gross profit

318.0k

Gross profit Margin, %

55%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

76.7m124.0m73.5m107.5m79.9m

Prepaid Expenses

6.7m8.7m5.6m

Inventories

5.6m2.7m

Current Assets

197.5m251.7m189.1m312.6m149.1m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

58.5m112.7m65.0m74.4m76.9m78.7m84.5m73.8m209.3m142.2m78.4m81.1m72.6m76.8m298.4m266.6m

Accounts Receivable

772.0k25.0k

Prepaid Expenses

2.1m1.2m5.0m3.8m2.3m2.6m5.3m6.1m8.4m6.8m6.5m8.2m6.9m6.8m4.6m4.0m

Inventories

4.1m5.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(35.8m)(80.8m)(131.3m)(210.8m)(248.5m)

Depreciation and Amortization

115.0k534.0k966.0k1.6m4.1m

Inventories

4.0m

Accounts Payable

1.1m(994.0k)2.3m2.7m6.2m
Quarterly
USDQ2, 2015

Financial Leverage

1.1 x
Show all financial metrics

Aimmune Therapeutics Operating Metrics

FY, 2016

Patents Issued

2
Show all operating metrics

Aimmune Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Aimmune Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Aimmune Therapeutics Online and Social Media Presence

Embed Graph

Aimmune Therapeutics Company Culture

  • Overall Culture

    A+

    90/100

  • CEO Rating

    A+

    85/100

  • Compensation

    A+

    92/100

Learn more on Comparably

Aimmune Therapeutics News and Updates

North America Allergy Immunotherapies Market Is Set for a Rapid Growth and is Expected to Reach USD Billion by 2027 - Johnson and Johnson Services, Inc., Aimmune Therapeutics, Anergis, Circassia

​The North America allergy immunotherapies market was valued at US$ 697.53 million in 2019 and is projected to reach US$ 1,634.17 million by 2027; it is expected to grow at a CAGR of 11.3 % during the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday

Aimmune Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm

Investors with losses are encouraged to contact the firm before November 21, 2020; click here to submit trade information

Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Northern District of California, Case No. 4:20-cv-06733-YGR, on behalf of common shareholders of Aimmune...

Nestlé completes acquisition of Aimmune Therapeutics

Vevey, October 14, 2020

Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.

VEVEY, Switzerland, Oct. 13, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") today announced the results of the tender offer by its wholly-owned subsidiary, SPN MergerSub, Inc. ("Purchaser"), to purchase all of the outstanding shares ("Shares") of common stock of Aimmune...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") (AIMT)...
Show more

Aimmune Therapeutics Blogs

European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU

European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU Content Import Mon, 12/21/2020 - 01:15 European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU December 21, 2020 …

Nestlé Completes Acquisition of Aimmune Therapeutics

Nestlé Completes Acquisition of Aimmune Therapeutics Ram.Romen@west.com Wed, 10/14/2020 - 01:53 Nestlé Completes Acquisition of Aimmune Therapeutics October 14, 2020 This release is a backfill from a News Wire General Nestlé announced…

Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science

Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science Content Import Mon, 08/31/2020 - 01:15 Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science …

Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers

LONDON --(BUSINESS WIRE)--Aug. 24, 2020-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that findings from APPEAL-2 ( A llergy to P eanuts Im P acting E motions A nd L

Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Content Import Fri, 08/07/2020 - 08:00 Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference August 07, 2020 This release is a backfil…

Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights

PALFORZIA ® launch gaining momentum as allergist offices begin to re-open EU and Swiss regulatory reviews for PALFORZIA remain on schedule Enrollment in phase 3 POSEIDON trial has resumed    $318 million cash, cash equivalents and investments Cost control measures limited second quarter EPS loss
Show more

Aimmune Therapeutics Frequently Asked Questions

  • When was Aimmune Therapeutics founded?

    Aimmune Therapeutics was founded in 2011.

  • Who are Aimmune Therapeutics key executives?

    Aimmune Therapeutics's key executives are Andrew Oxtoby, Eric Bjerkholt and Samina Bari.

  • How many employees does Aimmune Therapeutics have?

    Aimmune Therapeutics has 275 employees.

  • Who are Aimmune Therapeutics competitors?

    Competitors of Aimmune Therapeutics include Inovio Pharmaceuticals, Emisphere Technologies and Intercept Pharmaceuticals.

  • Where is Aimmune Therapeutics headquarters?

    Aimmune Therapeutics headquarters is located at 8000 Marina Blvd #200, Brisbane.

  • Where are Aimmune Therapeutics offices?

    Aimmune Therapeutics has offices in Brisbane, Durham, München, Dublin and in 1 other location.

  • How many offices does Aimmune Therapeutics have?

    Aimmune Therapeutics has 5 offices.